Printer Friendly

LOCAL BIOMEDICAL COMPANY FEATURED AT PRESTIGIOUS OAK RIDGE CONFERENCE TO BE HELD IN SAN DIEGO, APRIL 9-10

 LOCAL BIOMEDICAL COMPANY FEATURED AT PRESTIGIOUS
 OAK RIDGE CONFERENCE TO BE HELD IN SAN DIEGO, APRIL 9-10
 SAN DIEGO, April 3 /PRNewswire/ -- Diatron Corp., a local biomedical company has been selected as one of the presenters at the 24th annual Oak Ridge Conference, one of the most highly respected showcases for diagnostic medical products and services. Sponsored by the American Association for Clinical Chemistry, the Oak Ridge Conference will feature exceptional companies from all over the world that represent the laboratory of tomorrow.
 Diatron will present its unique patented transient-state fluoroimmunoassay (TS-FIA) technology, which represents important advances in diagnostic medicine. TS-FIA is the newest ultrasensitive fluorescence measurement system technology with a greater than 100 fold improvement in signal to background discrimination over the leading competitors in the clinical diagnostics marketplace.
 By integrating the two techniques of pulsed fluorescence and fluorescence polarization, Diatron has developed a simple, homogeneous "mix and read" immunoassay system that matches or exceeds the sensitivity of a wide variety of highly complex and costly heterogeneous "separation" technologies which have been the alternative in the clinical laboratory. At the heart of TS-FIA lies its two most powerful elements: novel and proprietary fluorescent dyes and miniaturized solid- state detection optics utilizing a highly reliable laser diode as the light source. To fully demonstrate the breadth and depth of TS-FIA, Diatron has developed representative homogeneous assays for therapeutic drug monitoring, infectious diseases and the monitoring of endocrine disorders.
 TS-FIA has applications from the high volume hospital and commercial reference laboratories down to locations nearer the doctor/patient setting. For several reasons, TS-FIA can perform rapid quantitative immunoassays at the point of patient care, such as the physicians office, patient's bedside, emergency room, or an ambulance.
 Any product embodying Diatron's patented technology and placed at the patient care level would eliminate the need to send blood samples to a laboratory for analysis. This would mean exceptionally fast reportable results, greater convenience for both patients and physicians, and lower labor costs. TS-FIA is the first technology with this capability and represents a major opportunity because it will not have any competitors in the marketplace.
 Transient-state fluoroimmunoassay is a simple "mix and read" system technology capable of being used with whole blood and providing test results in as little as five minutes. This scientific advance was initially developed by Dr. Walter Dandliker, Diatron's chief scientist and a director and, for more than 20 years, a biochemist at the Scripps Clinic and Research Foundation (La Jolla, Calif.). He has more than 80 publications in biophysical chemistry and immunochemistry.
 Diatron plans to introduce the FAST-60 System in the United States in 1993 by developing a corporate partnership with an established healthcare company. Diatron is presently in negotiation with several large corporations.
 -0- 4/3/92
 /CONTACT: Donald R. Marvin, president and CEO of Diatron Corp., 619-271-8727, or Neville Billimoria, president of Creative Marketing Directions, 619-792-0265, for Diatron/ CO: Diatron Corp. ST: California IN: MTC SU:


AL-CH -- SD001 -- 4875 04/03/92 13:53 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 3, 1992
Words:499
Previous Article:UNIONS, SENIORS TO HOLD PRESS CONFERENCE ON FLAT TAX
Next Article:SEPTA EXTENDS P.M. 'FREE FARE' HOURS ON BROAD STREET LINE TO HELP SENIOR CITIZENS MAKE RAILWORKS CONNECTIONS


Related Articles
Genetronics Announces Investor Conference Call Replay Starting July 28.
Breast cancer risk assessment technology of Biomedical Diagnostics accepted for presentation at National Cancer Conference.
AACC meetings.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters